Main Article Content
Chromatin deregulation is an emerging theme in cancer pathogenesis, and bladder cancer stands out among many other cancer types with frequent mutations of genes involved in epigenetic regulation. Defects in chromatin-level regulation can be manifested at multiple levels such as changes in DNA methylation, histone methylation patterns, and non-coding RNAs. Chromatin modifiers mutated in bladder cancer, such as KDM6A, KMT2D, KMT2C, ARID1A, EP300, have been studied in bladder cell line models. Also, there are studies that mapped the active regulatory landscape of bladder cancer and histone modification profiles. Collectively, existing literature emphasizes the importance of a thorough understanding of epigenetic deregulation in bladder cancer. The epigenetic signatures of bladder cancer can be targeted via epigenetic drugs or other genome editing tools, ultimately bringing specific treatment options for this cancer. This chapter provides an overview of the epigenetic modifications in bladder cancer, and the potential of epidrugs for the treatment of bladder cancer.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of individual chapters belongs to the respective authors. The authors grant unrestricted publishing and distribution rights to the publisher. The electronic versions of the chapters are published under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Users are allowed to share and adapt the chapters for any non-commercial purposes as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source. The books in their entirety are subject to copyright by the publisher. The reproduction, modification, republication and display of the books in their entirety, in any form, by anyone, for commercial purposes are strictly prohibited without the written consent of the publisher.